212 related articles for article (PubMed ID: 27916455)
1. Phosphodiesterase 10A Inhibition Improves Cortico-Basal Ganglia Function in Huntington's Disease Models.
Beaumont V; Zhong S; Lin H; Xu W; Bradaia A; Steidl E; Gleyzes M; Wadel K; Buisson B; Padovan-Neto FE; Chakroborty S; Ward KM; Harms JF; Beltran J; Kwan M; Ghavami A; Häggkvist J; Tóth M; Halldin C; Varrone A; Schaab C; Dybowski JN; Elschenbroich S; Lehtimäki K; Heikkinen T; Park L; Rosinski J; Mrzljak L; Lavery D; West AR; Schmidt CJ; Zaleska MM; Munoz-Sanjuan I
Neuron; 2016 Dec; 92(6):1220-1237. PubMed ID: 27916455
[TBL] [Abstract][Full Text] [Related]
2. TAK-063, a Novel Phosphodiesterase 10A Inhibitor, Protects from Striatal Neurodegeneration and Ameliorates Behavioral Deficits in the R6/2 Mouse Model of Huntington's Disease.
Harada A; Suzuki K; Kimura H
J Pharmacol Exp Ther; 2017 Jan; 360(1):75-83. PubMed ID: 27811172
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease.
Giampà C; Laurenti D; Anzilotti S; Bernardi G; Menniti FS; Fusco FR
PLoS One; 2010 Oct; 5(10):e13417. PubMed ID: 20976216
[TBL] [Abstract][Full Text] [Related]
4. Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's disease.
Kleiman RJ; Kimmel LH; Bove SE; Lanz TA; Harms JF; Romegialli A; Miller KS; Willis A; des Etages S; Kuhn M; Schmidt CJ
J Pharmacol Exp Ther; 2011 Jan; 336(1):64-76. PubMed ID: 20923867
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease.
Leuti A; Laurenti D; Giampà C; Montagna E; Dato C; Anzilotti S; Melone MA; Bernardi G; Fusco FR
Neurobiol Dis; 2013 Apr; 52():104-16. PubMed ID: 23220622
[TBL] [Abstract][Full Text] [Related]
6. PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington's disease mouse model.
Giralt A; Saavedra A; Carretón O; Arumí H; Tyebji S; Alberch J; Pérez-Navarro E
Hippocampus; 2013 Aug; 23(8):684-95. PubMed ID: 23576401
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase 10A inhibitor, MP-10 (PF-2545920), produces greater induction of c-Fos in dopamine D2 neurons than in D1 neurons in the neostriatum.
Wilson JM; Ogden AM; Loomis S; Gilmour G; Baucum AJ; Belecky-Adams TL; Merchant KM
Neuropharmacology; 2015 Dec; 99():379-86. PubMed ID: 26256420
[TBL] [Abstract][Full Text] [Related]
8. Current Understanding of PDE10A in the Modulation of Basal Ganglia Circuitry.
Schülke JP; Brandon NJ
Adv Neurobiol; 2017; 17():15-43. PubMed ID: 28956328
[TBL] [Abstract][Full Text] [Related]
9. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia.
Schmidt CJ; Chapin DS; Cianfrogna J; Corman ML; Hajos M; Harms JF; Hoffman WE; Lebel LA; McCarthy SA; Nelson FR; Proulx-LaFrance C; Majchrzak MJ; Ramirez AD; Schmidt K; Seymour PA; Siuciak JA; Tingley FD; Williams RD; Verhoest PR; Menniti FS
J Pharmacol Exp Ther; 2008 May; 325(2):681-90. PubMed ID: 18287214
[TBL] [Abstract][Full Text] [Related]
10. Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms.
Giorgi M; D'Angelo V; Esposito Z; Nuccetelli V; Sorge R; Martorana A; Stefani A; Bernardi G; Sancesario G
Eur J Neurosci; 2008 Sep; 28(5):941-50. PubMed ID: 18717735
[TBL] [Abstract][Full Text] [Related]
11. Relationship between subthalamic nucleus neuronal activity and electrocorticogram is altered in the R6/2 mouse model of Huntington's disease.
Callahan JW; Abercrombie ED
J Physiol; 2015 Aug; 593(16):3727-38. PubMed ID: 25952461
[TBL] [Abstract][Full Text] [Related]
12. PDE10A and PDE10A-dependent cAMP catabolism are dysregulated oppositely in striatum and nucleus accumbens after lesion of midbrain dopamine neurons in rat: a key step in parkinsonism physiopathology.
Giorgi M; Melchiorri G; Nuccetelli V; D'Angelo V; Martorana A; Sorge R; Castelli V; Bernardi G; Sancesario G
Neurobiol Dis; 2011 Jul; 43(1):293-303. PubMed ID: 21515371
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia.
Grauer SM; Pulito VL; Navarra RL; Kelly MP; Kelley C; Graf R; Langen B; Logue S; Brennan J; Jiang L; Charych E; Egerland U; Liu F; Marquis KL; Malamas M; Hage T; Comery TA; Brandon NJ
J Pharmacol Exp Ther; 2009 Nov; 331(2):574-90. PubMed ID: 19661377
[TBL] [Abstract][Full Text] [Related]
14. Comparison of phosphodiesterase 10A, dopamine receptors D1 and D2 and dopamine transporter ligand binding in the striatum of the R6/2 and BACHD mouse models of Huntington's disease.
Miller S; Hill Della Puppa G; Reidling J; Marcora E; Thompson LM; Treanor J
J Huntingtons Dis; 2014; 3(4):333-41. PubMed ID: 25575954
[TBL] [Abstract][Full Text] [Related]
15. Effect of chronic antipsychotic treatment on striatal phosphodiesterase 10A levels: a [¹¹C]MP-10 PET rodent imaging study with ex vivo confirmation.
Natesan S; Ashworth S; Nielsen J; Tang SP; Salinas C; Kealey S; Lauridsen JB; Stensbøl TB; Gunn RN; Rabiner EA; Kapur S
Transl Psychiatry; 2014 Apr; 4(4):e376. PubMed ID: 24690597
[TBL] [Abstract][Full Text] [Related]
16. Facilitation of corticostriatal transmission following pharmacological inhibition of striatal phosphodiesterase 10A: role of nitric oxide-soluble guanylyl cyclase-cGMP signaling pathways.
Padovan-Neto FE; Sammut S; Chakroborty S; Dec AM; Threlfell S; Campbell PW; Mudrakola V; Harms JF; Schmidt CJ; West AR
J Neurosci; 2015 Apr; 35(14):5781-91. PubMed ID: 25855188
[TBL] [Abstract][Full Text] [Related]
17. Dysregulation of the Basal Ganglia Indirect Pathway in Early Symptomatic
Callahan JW; Wokosin DL; Bevan MD
J Neurosci; 2022 Mar; 42(10):2080-2102. PubMed ID: 35058372
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase 10A inhibition is associated with locomotor and cognitive deficits and increased anxiety in mice.
Hebb AL; Robertson HA; Denovan-Wright EM
Eur Neuropsychopharmacol; 2008 May; 18(5):339-63. PubMed ID: 17913473
[TBL] [Abstract][Full Text] [Related]
19. Change in PDE10 across early Huntington disease assessed by [18F]MNI-659 and PET imaging.
Russell DS; Jennings DL; Barret O; Tamagnan GD; Carroll VM; Caillé F; Alagille D; Morley TJ; Papin C; Seibyl JP; Marek KL
Neurology; 2016 Feb; 86(8):748-54. PubMed ID: 26802091
[TBL] [Abstract][Full Text] [Related]
20. Voluntary saccade inhibition deficits correlate with extended white-matter cortico-basal atrophy in Huntington's disease.
Vaca-Palomares I; Coe BC; Brien DC; Campos-Romo A; Munoz DP; Fernandez-Ruiz J
Neuroimage Clin; 2017; 15():502-512. PubMed ID: 28649493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
